All In Biotech

Free tool

FAERS Monitor: Flavalta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216564 or its brand name (Flavalta, Epinephrine Bitartrate, Lidocaine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

22

Serious

19

86% of reports

Hospitalization

10

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use6
  • anaemia3
  • diarrhoea3
  • cytokine release syndrome2
  • dyspnoea2
  • emotional disorder2
  • facial paralysis2
  • fatigue2
  • infusion related reaction2
  • injection site pain2
  • local anaesthetic systemic toxicity2
  • poor quality product administered2
  • product contamination physical2
  • product use in unapproved indication2
  • vomiting2

Reports by year received

View as table
YearReports
20121
20164
20181
20192
20201
20217
20231
20253
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,137 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
local anaesthetic systemic toxicity21805.7481.02,025
product contamination physical2753.5200.9844
facial paralysis2224.459.8249
poor quality product administered2181.548.4201
cytokine release syndrome295.325.4104
emotional disorder262.016.567
infusion related reaction228.87.730
anaemiaSignal315.05.327
product use in unapproved indication27.72.16
off label useSignal66.63.324
injection site pain26.21.74
diarrhoeaSignal34.41.65
vomiting24.11.12
dyspnoea23.40.91
fatigue22.50.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.